flâneur

Kekulai

kekulai.com · 243 words · saved by 1 readers

Innovating at the intersection of AI and small molecule drug discovery

End-to-end agentic discovery for first-in-class drugs Every phase of drug discovery has dozens of bottlenecks, so fixing them one at a time doesn't fundamentally change its pace. That's why we put agents in the driver's seat across the whole arc. Our agents make the day-to-day decisions and know when to escalate to a scientist. With our platform, Allchymie, we now run the entire hit ID phase in 12 weeks, at a seventh of the industry cost. Investors Partners Our Team We assembled a team that can build drugs and agents together Hannah Shen, PhD Founder & CEO Early employee across…

saved by

related reading